Inhibition of tissue angiotensin-converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling

Circulation

Volumn 94, Issue 8, 1996, Pages 1941-1947

  Nong, Zengxuan ^a   Stassen, Jean Marie ^a   Moons, Lieve ^a   Collen, Désiré ^a   Janssens, Stefan ^b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

angiotension converting enzyme; hypoxia; pulmonary hypertension; vascular remodeling

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; QUINAPRIL;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL TONE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; HYPOXIA; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

EID: 0029800595     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.8.1941     Document Type: Article

References (42)

1. Reid L. The pulmonary circulation: remodeling in growth and disease. Am Rev Respir Dis. 1979;119:531-546.
2. Wagenvoort CA, Keutel J, Mooi WJ, Wagenvoort N. Longitudinal smooth muscle in pulmonary arteries: occurrence in congenital heart disease. Virchows Arch A Pathol Anal Histopathol. 1984;404:265-274.
3. Hunter C, Barer GR, Shaw JW, Clegg EJ. Growth of the heart and lungs in the hypoxic rodents: a model for human hypoxic disease. Clin Sci. 1974;46:375-391.
4. Suggett AJ, Barer GR. Experimental prevention of hypoxic pulmonary hypertension by drugs. Eur Heart J. 1988;9(suppl J):13-18.
5. Rabinovitch M, Gamble W, Nadas AL, Miettinen OS, Reid L. Rat pulmonary circulation after chronic hypertension: hemodynamic and structural features. Am J Physiol. 1979;236:H818-H827.
6. Janssens SP, Thompson BT, Spence CR, Hales CA. Polycythemia and vascular remodeling in chronic hypoxic pulmonary hypertension in guinea pigs. J Appl Physiol. 1991;71:2218-2223.
7. Mckenzie JC, Hung K, Mattoli L, Klein RM. Reduction in hypertension-induced protein synthesis in the rat pulmonary trunk after treatment with teprotide (SO 20881). Proc Soc Exp Med. 1984;177:377-382.
8. Hatakeyama H, Miyamori I, Fujita T, Takeda Y, Takeda R, Yamamoto H. Vascular aldosterone: biosynthesis and a link to angiotensin II-induced hypertension of vascular smooth muscle cell. J Biol Chem. 1994;269:24316-24320.
9. Linz W, Wiemer G, Scholkens BA. Contribution of bradykinin to the cardiovascular effects of ramipril. J Cardiovasc Pharmacol. 1993;22(suppl 9):S1-S8.
10. Johnston CI, Jandeleit K, Mooser V, Katapothis A, Perich R, Paxton D, Murohara Y, Jackson B. Angiotensin-converting enzyme and its inhibition in the heart and vessels. J Cardiovasc Pharmacol. 1992;20(suppl B):S6-S12.
11. King SJ, Booyse FM, Lin P, Traylor M, Narkates AJ, Oparil S. Hypoxia stimulates endothelial cell angiotensin-converting enzyme antigen synthesis. Am J Physiol. 1989;256:C1231-C1238.
12. Molteni A, Zakheim RM, Mullis KB, Mattioli L. The effect of chronic alveolar hypoxia on lung and serum angiotensin converting enzyme activity. Proc Soc Exp Biol Med. 1974;147:263-265.
13. Bertoli L, Cicero SL, Busnardo I, Rizzato G, Montanari G. Effects of captopril on hemodynamics and blood gases in chronic obstructive lung disease with pulmonary hypertension. Respiration. 1986;49:251-256.
14. Rich S, Martinez J, Lam W, Rosen KM. Captopril as treatment for patients with pulmonary hypertension. Br Heart J. 1982;48:272-277.
15. Peacock AJ, Matthews A. Transpulmonary angiotensin II formation and pulmonary haemodynamics in stable hypoxic lung disease: the effect of captopril. Respir Med. 1992;86:21-27.
16. Dzau VJ. Vascular renin-angiotensin system and vascular protection. J Cordiovasc Pharmacol. 1993;22(suppl 5):S1-S9.
17. Fabris B, Chen B, Pupic V. Perich R, Johnston CI. Inhibition of angiotensin-converting enzyme (ACE) in plasma and tissue. J Cardiovasc Pharmacol. 1990;15(suppl):S6-S13.
18. Saynavalammi P, Porsti I, Porsti P. Effects of the converting enzyme inhibitor quinapril (CI-906)on blood pressure, renin-angiotensin system, and prostanoids in essential hypertension. J Cardiovasc Pharmacol. 1988;12:88-93.
19. Banas JS. Preliminary bemodynamic report of the efficacy and safety of quinapril in acute and chronic treatment of patients with congestive heart failure. Angiology. 1989;40:396-401.
20. Melby JC. Angiotensin-converting enzyme in cardiovacular and adrenal tissues and implications for successful blood pressure management. Am J Cardiol. 1992;69:2-7.
21. Rakugi H, Wang DS, Dzau VJ, Pratt RE. Potential importance of tissue angiotensin-converting enzyme inhibition in preventing neointima formation. Circulation. 1994;90:449-455.
22. Neyses L, Nouskas J, Oberdorf S, Vetter H. Action of an ACE inhibitor on myocardial early growth response. J Cardiovasc Pharmacol. 1992;20(suppl B):S12-S14.
23. 3H-thymidine by cells of the rat pulmonary arteries and alveolar wall. Am J Pathol. 1979;96:51-70.
24. Thompson BT, Hassoun PM, Kradin RL, Hales CA. Acute and chronic hypoxic pulmonary hypertension in guinea pigs. J Appl Physiol. 1989;66:920-928.
25. Fulton RM, Hutchison EC, Jones AM. Ventricular weight in cardiac hypertrophy. Br Heart J. 1952;14:413-420.
26. Mcgavran PD, Moore LB, Brody AR. Inhalation of chrysotile asbestos induces rapid cellular proliferation in small pulmonary vessels of mice and rats. Am J Pathol. 1990;136:695-705.
27. Weir EK. Does normoxic pulmonary vasodilation rather than hypoxic vasoconstriction account for the pulmonary pressure response to hypoxia? Lancet. 1978;1:289-296.
28. Kentera D, Susie D, Cvetkovic A, Djordjevic G. Effects of SO 14.225, an orally active inhibitor of angiotensin-converting enzyme, on hypoxic pulmonary hypertension and right ventricular hypertrophy in rats. Basic Res Cardiol. 1981;76:344-351.
29. Berkov S. Hypoxic pulmonary vasoconstriction in rat: the necessary role of angiotensin II. Circ Res. 1974;35:256-261.
30. Suggett AJ, Mohammed FH, Barer GR. Angiotensin, hypoxia, verapamil, and pulmonary vessels. Clin Exp Pharmacol Physiol. 1980;7:263-274.
31. Hales CA, Rouse ET, Kazemi H. Failure of saralasin acetate, a competitive inhibitor of angiotensin II, to diminish alveolar hypoxic vasoconstriction in the dog. Cardiovasc Res. 1977;11:541-546.
32. Stanbrook HS, Morris KG, McMurtry IF. Prevention and reversal of hypoxic pulmonary hypertension by calcium antagonists. Am Rev Respir Dis. 1984;130:81-85.
33. Zakheim RM, Mattioli L, Molteni A, Mullis KB, Bartley J. Prevention of pulmonary vascular changes of chronic alveolar hypoxia by inhibition of angiotensin I-converting enzyme in the rat. Lab Invest. 1975;33:57-61.
34. Clozel JP, Saunier C, Hartemann D, Fischli W. Effects of cilazapril, a novel angiotensin converting enzyme inhibitor, on the structure of pulmonary arteries of rats exposed to chronic hypoxia. J Cardiovasc Pharmacol. 1991;17:36-40.
35. Abraham WT, Raynolds MV, Gottschall B, Badesch DB, Wynne KM, Groves BM, Lowes BD, Bristow MR, Perryman MB, Voelkel NF. Importance of angiotensin-converting enzyme in pulmonary hypertension. Cardiology. 1995;86(suppl 1):9-15.
36. Morishita R, Gibbons GH, Ellison KE, Lee W, Zhang L, Yu H, Kaneda Y, Ogihara T, Dzau VJ. Evidence for direct local effect of angiotensin in vascular hypertrophy. J Clin Invest. 1994;94:978-984.
37. Daemen MJAP, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res. 1991;68:450-456.
38. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs hyperplasia: autocrine transforming growth factor-beta I expression determines growth response to angiotensin II. J Clin Invest. 1992;90:456-461.
39. Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest. 1993;91:2268-2274.
40. Johnston C. Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair, and remodeling. Hypertension. 1994;23:258-268.
41. Garg UC, Hassi A. Nitric oxide-generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 1986;83:1774-1777.
42. Malinski T, Kapturczak M, Dayharsh J, Bohr D. Nitric oxide synthase activity in genetic hypertension. Biochem Biophys Res Commun. 1993;194:654-658.